The failure of Novartis's Lp(a) study was foreshadowed by its extended timeline. When events in an outcome-based trial occur slower than modeled, it suggests a mispowered study or misunderstood background factors, almost always leading to a negative result. Amgen's similar issue is a warning sign.

Recent failures in trials for hsCRP and Lp(a) targets highlight a growing challenge in cardiovascular R&D. Existing treatments like statins and GLP-1s have raised the standard of care so high that proving an incremental benefit for a new drug is incredibly difficult, requiring massive, expensive, and often unsuccessful studies.

While pioneering antisense oligonucleotide (ASO) therapies, Ionis faced immense scientific and financial hurdles with no guarantee of success. Competitors like Gilead abandoned the field, but Ionis persevered through decades of uncertainty, ultimately proving the viability of the new drug modality.

The upcoming Phase 3 data for Pelacarsen is the first to test the LP(a) reduction hypothesis. Since it has lower efficacy than competitors, a positive result would validate the target for the entire field, including three other Phase 3 programs, and influence preclinical development decisions.

The catastrophic failure rate in drug development isn't just bad luck; it's a structural problem. It originates from the very first decision: researchers, biased by existing literature and simplistic models, fixate on a single biochemical target, ignoring the body's complex, multi-faceted nature.

Novartis's Lp(a) drug may have failed not because the target is wrong, but because patients were already so well-treated with existing drugs like statins. This highlights a growing challenge: new therapies must demonstrate significant added value over an increasingly effective standard of care.

The surprising failures of Novartis's and Novo Nordisk's heart drugs, both targeting 'genetically validated' pathways, have debunked the widely held belief that genetic data guarantees clinical success. This forces a fundamental rethink of using genetics to de-risk massive drug development investments.

Two major cardiovascular trials targeting novel biomarkers (LPA and hs-CRP) failed to improve outcomes despite successfully lowering the biomarkers. This has dampened enthusiasm for novel targets and shifted R&D and investor focus back to established, "unsexy" pathways like PCSK9, GLP-1, and SGLT2, which are now viewed as less risky.

The failed trial is puzzling because the drug showed zero benefit on top of standard-of-care tefamidis, even on biomarkers. This wasn't just a missed endpoint; it suggests the widely held hypothesis that combining a TTR stabilizer with a TTR silencer provides synergistic benefit may be flawed, impacting future trial designs and strategies.